On October 7, 2022, the U.S. Department of Commerce published new regulations restricting the export to China of advanced semiconductors, supercomputer technology, equipment for the manufacturing of advanced semiconductors and components and technology for the manufacturing in China of certain semiconductor manufacturing equipment. The new restrictions are lengthy and complex. Teradyne continues to assess the impact of these regulations on its business. At this time, the Company has determined that restrictions on the sale of semiconductor testers in China to test certain advanced semiconductors will impact Teradyne’s sales to certain companies in China. Several multinational companies manufacturing these advanced semiconductors in China have obtained one-year licenses allowing suppliers such as Teradyne to continue to provide testers to the facilities operated by these companies. We expect that other companies manufacturing advanced semiconductors in China will not receive licenses, thereby restricting Teradyne’s ability to provide testers to the facilities operated by these companies that do not receive a license. The Company also is assessing the filing of license requests to sell to and support certain customers in China for certain end uses that, if granted, may reduce the impact of these restrictions on the Company’s business. At this time, Teradyne does not know the impact these end user and end use restrictions will have on its business in China or on future revenues. In addition to the specific restrictions impacting Teradyne’s business, the regulations may have an adverse impact on certain actual or potential customers and on the global semiconductor industry. To the extent the regulations impact actual and potential customers or disrupt the global semiconductor industry, Teradyne’s business and revenues will be adversely impacted.
The Company also has determined that the restrictions on the export of certain US origin components and technology for use in the development and production in China of certain semiconductor manufacturing equipment impact its manufacturing and development operations in China. Teradyne has received a temporary authorization from the Department of Commerce allowing the Company to continue its manufacturing and development operations in China until the Department of Commerce issues a license to replace this temporary authorization. Teradyne will file an application with the Department of Commerce for a license to replace the temporary authorization by November 17, 2022. The Company cannot assess the likelihood or timing of receiving this license. In addition to requesting a license, the Company is implementing procedures for minimizing the impact of these new regulations, but there is no assurance that these procedures will succeed.
Following Russia’s invasion of Ukraine in February 2022, the U.S. and other countries imposed significant sanctions against the Russian government and many Russian companies and individuals. Although Teradyne does not have significant operations in Russia, the sanctions could impact Teradyne’s business in other countries and could have a negative impact on the Company’s supply chain, either of which could adversely affect Teradyne’s business and financial results.
COVID-19 has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, government vaccination mandates and other government regulations. These measures have impacted and may further impact Teradyne’s workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers. As Teradyne implements measures to comply with additional regulations, the Company may experience increased compliance costs, increased risk of non-compliance and increased risk of employee attrition.
The COVID-19 pandemic has adversely impacted the Company’s results of operations, including increased costs company-wide and constraints within the Company’s supply chain. The Company cannot accurately estimate the amount of the impact on Teradyne’s 2022 financial results and to its future financial results. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne’s markets. This uncertainty resulted in a significant decrease in demand for certain Teradyne products and could continue to impact demand for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of in person participation in meetings, events and conferences) and the Company may take further actions as may be required by government authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne’s ability to perform critical functions could be impacted. The degree to which COVID-19 continues to impact Teradyne’s results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the virus, its severity, the actions to contain the virus or the availability and impact of vaccines in countries where the Company does business, and how quickly and to what extent normal economic and operating conditions can resume.
Important factors that could cause actual results, the 2024 earnings model, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne’s financial condition; the continued impact of the COVID-19 pandemic and related government responses on the market and demand for Teradyne’s products, on its contract manufacturers and supply chain, and on its workforce; the impact of the global semiconductor supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; demand for products by the Company’s largest customers; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the Company’s best interests; additional U.S. tax regulations or IRS guidance; the impact of any tariffs or export controls imposed by the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; the impact of U.S. Department Commerce export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela; sanctions imposed against the Russian government and certain Russian companies and individuals by the U.S., and other countries; the impact of regulations published by the U.S. Department of Commerce relating to semiconductors and semiconductor manufacturing equipment destined for certain end uses in China; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the “Risk Factors” sections of Teradyne’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 3, 2022. The forward-looking statements provided by Teradyne in this press release represent management’s views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management’s views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne’s views as of any date subsequent to the date of this release.
TERADYNE, INC. REPORT FOR THIRD FISCAL QUARTER OF 2022 | ||||||||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||||||||
Quarter Ended | Nine Months Ended | |||||||||||||||||||||||
October 2,
2022 |
July 3,
2022 |
October 3,
2021 |
October 2,
2022 |
October 3,
2021 | ||||||||||||||||||||
Net revenues | $ | 827,073 | $ | 840,766 | $ | 950,501 | $ | 2,423,209 | $ | 2,817,835 | ||||||||||||||
Cost of revenues (exclusive of acquired intangible assets amortization shown separately below) (1) | 341,694 | 334,377 | 379,500 | 976,508 | 1,138,227 | |||||||||||||||||||
Gross profit | 485,379 | 506,389 | 571,001 | 1,446,701 | 1,679,608 | |||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||
Selling and administrative | 135,632 | 139,533 | 134,829 | 415,351 | 404,812 | |||||||||||||||||||
Engineering and development | 111,715 | 111,951 | 107,220 | 331,781 | 317,644 | |||||||||||||||||||
Acquired intangible assets amortization | 4,729 | 4,871 | 5,355 | 14,663 | 16,293 | |||||||||||||||||||
Restructuring and other (2) | 1,796 | 2,044 | 1,197 | 19,554 | (3,426 | ) | ||||||||||||||||||
Operating expenses | 253,872 | 258,399 | 248,601 | 781,349 | 735,323 | |||||||||||||||||||
Income from operations | 231,507 | 247,990 | 322,400 | 665,352 | 944,285 | |||||||||||||||||||
Interest and other expense (3) | 5,310 | 9,398 | 24,645 | 20,204 | 38,511 | |||||||||||||||||||
Income before income taxes | 226,197 | 238,592 | 297,755 | 645,148 | 905,774 | |||||||||||||||||||
Income tax provision | 42,712 | 40,805 | 41,037 | 101,948 | 115,225 | |||||||||||||||||||
Net income | $ | 183,485 | $ | 197,787 | $ | 256,718 | $ | 543,200 | $ | 790,549 | ||||||||||||||
Net income per common share: | ||||||||||||||||||||||||
Basic | $ | 1.17 | $ | 1.24 | $ | 1.56 | $ | 3.41 | $ | 4.77 | ||||||||||||||
Diluted | $ | 1.10 | $ | 1.16 | $ | 1.41 | $ | 3.17 | $ | 4.26 | ||||||||||||||
Weighted average common shares - basic | 156,364 | 159,563 | 164,583 | 159,325 | 165,690 | |||||||||||||||||||
Weighted average common shares - diluted (4) | 166,733 | 171,159 | 181,987 | 171,156 | 185,492 | |||||||||||||||||||
Cash dividend declared per common share | $ | 0.11 | $ | 0.11 | $ | 0.10 | $ | 0.33 | $ | 0.30 | ||||||||||||||
(1 | ) | Cost of revenues includes: | Quarter Ended | Nine Months Ended | ||||||||||||||||||||
October 2,
2022 |
July 3,
2022 |
October 3,
2021 |
October 2,
2022 |
October 3,
2021 | ||||||||||||||||||||
Provision for excess and obsolete inventory | $ | 12,234 | $ | 5,105 | $ | 8,149 | $ | 18,929 | $ | 11,775 | ||||||||||||||
Sale of previously written down inventory | (269 | ) | (449 | ) | (824 | ) | (980 | ) | (2,043 | ) | ||||||||||||||
$ | 11,965 | $ | 4,656 | $ | 7,325 | $ | 17,949 | $ | 9,732 | |||||||||||||||
(2 | ) | Restructuring and other consists of: | Quarter Ended | Nine Months Ended | ||||||||||||||||||||
October 2,
2022 |
July 3,
2022 |
October 3,
2021 |
October 2,
2022 |
October 3,
2021 | ||||||||||||||||||||
Employee severance | $ | 1,215 | $ | 383 | $ | 617 | $ | 2,148 | $ | 1,242 | ||||||||||||||
Litigation settlement | - | - | - | 14,700 | - | |||||||||||||||||||
Acquisition related expenses and compensation | - | - | 275 | (201 | ) | 313 | ||||||||||||||||||
Contingent consideration fair value adjustment | - | - | - | - | (7,227 | ) | ||||||||||||||||||
Other | 581 | 1,661 | 305 | 2,907 | 2,246 | |||||||||||||||||||
$ | 1,796 | $ | 2,044 | $ | 1,197 | $ | 19,554 | $ | (3,426 | ) | ||||||||||||||
(3 | ) | Interest and other includes: | Quarter Ended | Nine Months Ended | ||||||||||||||||||||
October 2,
2022 |
July 3,
2022 |
October 3,
2021 |
October 2,
2022 |
October 3,
2021 | ||||||||||||||||||||
Loss on convertible debt conversions | $ | - | $ | - | $ | 20,153 | $ | - | $ | 25,397 | ||||||||||||||
Non-cash convertible debt interest | - | - | 2,262 | - | 9,120 | |||||||||||||||||||
Pension actuarial gains | - | - | - | - | (627 | ) | ||||||||||||||||||
$ | - | $ | - | $ | 22,415 | $ | - | $ | 33,890 | |||||||||||||||
(4 | ) | Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended October 2, 2022, July 3, 2022, and October 3, 2021, 1.5 million, 1.9 million and 6.5 million shares, respectively, have been included in diluted shares. For the nine months ended October 2, 2022 and October 3, 2021, 2.0 million and 8.8 million shares, respectively, have been included in diluted shares. For the quarters ended October 2, 2022, July 3, 2022 and October 3, 2021, diluted shares also included 8.3 million, 9.0 million and 9.8 million shares, respectively, from the convertible note hedge transaction. For the nine months ended October 2, 2022 and October 3, 2021, diluted shares included 9.1 million and 9.8 million shares, respectively, from the convertible note hedge transaction.
| ||||||||||||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) | ||||||||||||||||||||||||
October 2,
2022 |
December 31,
2021 | |||||||||||||||||||||||
Assets | ||||||||||||||||||||||||
Cash and cash equivalents | $ | 710,746 | $ | 1,122,199 | ||||||||||||||||||||
Marketable securities | 65,310 | 244,231 | ||||||||||||||||||||||
Accounts receivable, net | 530,349 | 550,749 | ||||||||||||||||||||||
Inventories, net | 310,754 | 243,330 | ||||||||||||||||||||||
Prepayments | 502,678 | 406,266 | ||||||||||||||||||||||
Other current assets | 7,717 | 9,452 | ||||||||||||||||||||||
Total current assets | 2,127,554 | 2,576,227 | ||||||||||||||||||||||
Property, plant and equipment, net | 415,181 | 387,240 | ||||||||||||||||||||||
Operating lease right-of-use assets, net | 61,430 | 68,807 | ||||||||||||||||||||||
Marketable securities | 111,039 | 133,858 | ||||||||||||||||||||||
Deferred tax assets | 130,207 | 102,428 | ||||||||||||||||||||||
Retirement plans assets | 13,805 | 15,110 | ||||||||||||||||||||||
Other assets | 29,311 | 24,096 | ||||||||||||||||||||||
Acquired intangible assets, net | 55,580 | 75,635 | ||||||||||||||||||||||
Goodwill | 375,799 | 426,024 | ||||||||||||||||||||||
Total assets | $ | 3,319,906 | $ | 3,809,425 | ||||||||||||||||||||
Liabilities | ||||||||||||||||||||||||
Accounts payable | $ | 167,975 | $ | 153,133 | ||||||||||||||||||||
Accrued employees' compensation and withholdings | 168,102 | 253,667 | ||||||||||||||||||||||
Deferred revenue and customer advances | 143,591 | 146,185 | ||||||||||||||||||||||
Other accrued liabilities | 126,457 | 124,187 | ||||||||||||||||||||||
Operating lease liabilities | 17,079 | 19,977 | ||||||||||||||||||||||
Income taxes payable | 64,141 | 88,789 | ||||||||||||||||||||||
Current debt | 14,596 | 19,182 | ||||||||||||||||||||||
Total current liabilities | 701,941 | 805,120 | ||||||||||||||||||||||
Retirement plans liabilities | 137,317 | 151,141 | ||||||||||||||||||||||
Long-term deferred revenue and customer advances | 48,488 | 54,921 | ||||||||||||||||||||||
Long-term other accrued liabilities | 15,506 | 15,497 | ||||||||||||||||||||||
Deferred tax liabilities | 1,327 | 6,327 | ||||||||||||||||||||||
Long-term operating lease liabilities | 51,872 | 56,178 | ||||||||||||||||||||||
Long-term income taxes payable | 59,135 | 67,041 | ||||||||||||||||||||||
Debt | 50,195 | 89,244 | ||||||||||||||||||||||
Total liabilities | 1,065,781 | 1,245,469 | ||||||||||||||||||||||
Mezzanine equity | - | 1,512 | ||||||||||||||||||||||
Shareholders' equity | 2,254,125 | 2,562,444 | ||||||||||||||||||||||
Total liabilities, convertible common shares and shareholders’ equity | $ | 3,319,906 | $ | 3,809,425 | ||||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) | ||||||||||||||||||||||||
Quarter Ended | Nine Months Ended | |||||||||||||||||||||||
October 2,
2022 |
October 3,
2021 |
October 2,
2022 |
October 3,
2021 | |||||||||||||||||||||
Cash flows from operating activities: | ||||||||||||||||||||||||
Net income | $ | 183,485 | $ | 256,718 | $ | 543,200 | $ | 790,549 | ||||||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||||||||||
Depreciation | 23,442 | 22,018 | 67,902 | 67,866 | ||||||||||||||||||||
Stock-based compensation | 12,298 | 11,418 | 37,420 | 34,649 | ||||||||||||||||||||
Provision for excess and obsolete inventory | 12,234 | 8,149 | 18,929 | 11,775 | ||||||||||||||||||||
Amortization | 4,917 | 8,283 | 15,012 | 27,626 | ||||||||||||||||||||
Losses (gains) on investments | 2,463 | (100 | ) | 11,436 | (4,750 | ) | ||||||||||||||||||
Deferred taxes | (4,776 | ) | (9,932 | ) | (28,373 | ) | (10,732 | ) | ||||||||||||||||
Contingent consideration fair value adjustment | - | - | - | (7,227 | ) | |||||||||||||||||||
Retirement plans actuarial gains | - | - | - | (627 | ) | |||||||||||||||||||
Loss on convertible debt conversions | - | 20,153 | - | 25,397 | ||||||||||||||||||||
Other | 218 | 45 | 740 | 243 | ||||||||||||||||||||
Changes in operating assets and liabilities | ||||||||||||||||||||||||
Accounts receivable | 150,632 | 269,399 | 4,248 | (103,299 | ) | |||||||||||||||||||
Inventories | (22,135 | ) | 2,035 | (68,817 | ) | 21,943 | ||||||||||||||||||
Prepayments and other assets | 420 | (21,148 | ) | (94,331 | ) | (138,564 | ) | |||||||||||||||||
Accounts payable and other liabilities | (28,071 | ) | (21,726 | ) | (71,682 | ) | 65,064 | |||||||||||||||||
Deferred revenue and customer advances | (20,059 | ) | (6,490 | ) | (5,896 | ) | 8,699 | |||||||||||||||||
Retirement plans contributions | (1,279 | ) | (1,384 | ) | (3,897 | ) | (4,123 | ) | ||||||||||||||||
Income taxes | (42,185 | ) | (14,778 | ) | (31,370 | ) | (17,406 | ) | ||||||||||||||||
Net cash provided by operating activities | 271,604 | 522,660 | 394,521 | 767,083 | ||||||||||||||||||||
Cash flows from investing activities: | ||||||||||||||||||||||||
Purchases of property, plant and equipment | (38,929 | ) | (29,205 | ) | (128,672 | ) | (103,162 | ) | ||||||||||||||||
Purchases of marketable securities | (19,294 | ) | (111,384 | ) | (267,175 | ) | (509,470 | ) | ||||||||||||||||
Proceeds from sales of marketable securities | 115,558 | 93,325 | 259,200 | 209,437 | ||||||||||||||||||||
Proceeds from maturities of marketable securities | 42,440 | 111,064 | 182,092 | 571,277 | ||||||||||||||||||||
Purchase of investment | - | - | - | (12,000 | ) | |||||||||||||||||||
Net cash provided by investing activities | 99,775 | 63,800 | 45,445 | 156,082 | ||||||||||||||||||||
Cash flows from financing activities: | ||||||||||||||||||||||||
Repurchase of common stock | (217,201 | ) | (209,596 | ) | (750,000 | ) | (406,180 | ) | ||||||||||||||||
Dividend payments | (17,136 | ) | (16,440 | ) | (52,578 | ) | (49,711 | ) | ||||||||||||||||
Payments of convertible debt principal | (9,713 | ) | (235,169 | ) | (52,005 | ) | (301,997 | ) | ||||||||||||||||
Payments related to net settlement of employee stock compensation awards | (207 | ) | (251 | ) | (32,987 | ) | (32,045 | ) | ||||||||||||||||
Issuance of common stock under stock purchase and stock option plans | 12,197 | 9 | 28,733 | 32,590 | ||||||||||||||||||||
Net cash used for financing activities | (232,060 | ) | (461,447 | ) | (858,837 | ) | (757,343 | ) | ||||||||||||||||
Effects of exchange rate changes on cash and cash equivalents | (596 | ) | - | 7,418 | (489 | ) | ||||||||||||||||||
Increase (decrease) in cash and cash equivalents | 138,723 | 125,013 | (411,453 | ) | 165,333 | |||||||||||||||||||
Cash and cash equivalents at beginning of period | 572,023 | 954,441 | 1,122,199 | 914,121 | ||||||||||||||||||||
Cash and cash equivalents at end of period | $ | 710,746 | $ | 1,079,454 | $ | 710,746 | $ | 1,079,454 | ||||||||||||||||